Rewriting Life

Saved by the Snake?

Cobra venom is deadly stuff (about 20,000 fatalities a year globally), but it may also be a healer. A new drug derived from the venom has shown promise against multiple sclerosis (MS) and sister diseases affecting the nervous and immune systems. PhyloMed, a pharmaceutical company in Plantation, Fla., has synthesized a harmless peptide (small protein) from constituents of the snake’s venom, that acts as a kind of decoy. Attacks by immune system cells on myelin-the fatty material surrounding nerve fibers-disrupt signals between nerve cells to create characteristic MS lesions and paralysis. Neurotoxins from cobra venom paralyze nerve cells in much the same way. By binding to nerve cell receptors as a modified peptide instead of as a toxin, the venom-derived drug, called Immunokine, morphs into a therapeutic agent that can reverse MS’s debilitating effects. Clinical trials slated for this summer will target MS and adrenomyeloneuropathy (a progressive genetic disorder of the adrenal gland that results in nervous system deterioration).

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Premium.
  • Insider Premium {! insider.prices.premium !}*

    {! insider.display.menuOptionsLabel !}

    Our award winning magazine, unlimited access to our story archive, special discounts to MIT Technology Review Events, and exclusive content.

    See details+

    What's Included

    Bimonthly magazine delivery and unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

    First Look: exclusive early access to important stories, before they’re available to anyone else

    Insider Conversations: listen in on in-depth calls between our editors and today’s thought leaders

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.